Literature DB >> 22014576

An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.

Aikseng Ooi1, Jing-Chii Wong, David Petillo, Douglas Roossien, Victoria Perrier-Trudova, Douglas Whitten, Bernice Wong Hui Min, Min-Han Tan, Zhongfa Zhang, Ximing J Yang, Ming Zhou, Betty Gardie, Vincent Molinié, Stéphane Richard, Puay Hoon Tan, Bin Tean Teh, Kyle A Furge.   

Abstract

Fumarate hydratase (FH) mutation causes hereditary type 2 papillary renal cell carcinoma (PRCC2). The main effect of FH mutation is fumarate accumulation. The current paradigm posits that the main consequence of fumarate accumulation is HIF-α stabilization. Paradoxically, FH mutation differs from other HIF-α stabilizing mutations, such as VHL and SDH mutations, in its associated tumor types. We identified that fumarate can directly up-regulate antioxidant response element (ARE)-controlled genes. We demonstrated that aldo-keto reductase family 1 member B10 (AKR1B10) is an ARE-controlled gene and is up-regulated upon FH knockdown as well as in FH null cell lines. AKR1B10 overexpression is also a prominent feature in both hereditary and sporadic PRCC2. This phenotype better explains the similarities between hereditary and sporadic PRCC2.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014576     DOI: 10.1016/j.ccr.2011.08.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  177 in total

1.  Kidney tumours. 'NRF said.

Authors:  Nicola McCarthy
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

Review 2.  Cellular metabolism and disease: what do metabolic outliers teach us?

Authors:  Ralph J DeBerardinis; Craig B Thompson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 3.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

Review 4.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 5.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

Review 6.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 7.  Filtering through the role of NRF2 in kidney disease.

Authors:  Cody J Schmidlin; Matthew B Dodson; Donna D Zhang
Journal:  Arch Pharm Res       Date:  2019-08-01       Impact factor: 4.946

8.  Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.

Authors:  Masataka Kanno; Kazunori Kawaguchi; Masao Honda; Rika Horii; Hajime Takatori; Tetsuro Shimakami; Kazuya Kitamura; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2019-02-01       Impact factor: 7.527

9.  An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.

Authors:  Andrew C Nelson; Nischalan Pillay; Stephen Henderson; Nadège Presneau; Roberto Tirabosco; Dina Halai; Fitim Berisha; Paul Flicek; Derek L Stemple; Claudio D Stern; Fiona C Wardle; Adrienne M Flanagan
Journal:  J Pathol       Date:  2012-09-26       Impact factor: 7.996

Review 10.  Metabolism of kidney cancer: from the lab to clinical practice.

Authors:  Sunil Sudarshan; Jose A Karam; James Brugarolas; R Houston Thompson; Robert Uzzo; Brian Rini; Vitaly Margulis; Jean-Jacques Patard; Bernard Escudier; W Marston Linehan
Journal:  Eur Urol       Date:  2012-09-28       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.